2R,6R-Hydroxynorketamine hydrochloride

Pricing Availability   Qty
Description: Enhances AMPA currents; decreases D-serine (a NMDA co-agonist); lacks ketamine-related side effects
Chemical Name: (2R,6R)-2-Amino-2-(2-chlorophenyl)-6-hydroxycyclohexanone hydrochloride
Purity: ≥98% (HPLC)
Citations (10)
Literature (2)

Biological Activity for 2R,6R-Hydroxynorketamine hydrochloride

2R,6R-Hydroxynorketamine hydrochloride is a ketamine metabolite. It enhances AMPA receptor-mediated excitatory post-synaptic potentials in the CA1 region of hippocampal slices and decreases intracellular D-serine (a NMDA co-agonist) concentrations in PC-12 cells (IC50 = 0.68 nM). 2R,6R-Hydroxynorketamine upregulates KCNQ2 channels in mouse ventral hippocampal glutamatergic neurons in vitro and in vivo. Exerts antidepressant effects in mice. Lacks ketamine-related side effects.

2S,6S-Enantiomer and Racemate also available.

Licensing Information

Sold under license from the NIH, US patent 62/313,309

Technical Data for 2R,6R-Hydroxynorketamine hydrochloride

M. Wt 276.16
Formula C12H14ClNO2.HCl
Storage Store at RT
Purity ≥98% (HPLC)
CAS Number 1430202-69-9
PubChem ID 121513910
Smiles ClC1=C([C@@]2(N)C([C@H](O)CCC2)=O)C=CC=C1.Cl

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for 2R,6R-Hydroxynorketamine hydrochloride

Solvent Max Conc. mg/mL Max Conc. mM
water 13.81 50
DMSO 27.62 100

Preparing Stock Solutions for 2R,6R-Hydroxynorketamine hydrochloride

The following data is based on the product molecular weight 276.16. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 3.62 mL 18.11 mL 36.21 mL
5 mM 0.72 mL 3.62 mL 7.24 mL
10 mM 0.36 mL 1.81 mL 3.62 mL
50 mM 0.07 mL 0.36 mL 0.72 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Product Datasheets for 2R,6R-Hydroxynorketamine hydrochloride

Certificate of Analysis / Product Datasheet
Select another batch:

References for 2R,6R-Hydroxynorketamine hydrochloride

References are publications that support the biological activity of the product.

Singh et al (2016) KA metabolites enantioselectively decrease intracellular D-serine concentrations in PC-12 cells. PLoS One 11 e0149499 PMID: 27096720

Zanos et al (2016) NMDAR inhibition-independent antidepressant actions of KA metabolites. Nature 533 481 PMID: 27144355

Lopez et al (2022) Ketamine exerts its sustained antidepressant effects via cell-type-specific regulation of Kcnq2. Neuron 110 2283 PMID: 35649415

If you know of a relevant reference for 2R,6R-Hydroxynorketamine hydrochloride, please let us know.

Keywords: 2R,6R-Hydroxynorketamine hydrochloride, 2R,6R-Hydroxynorketamine hydrochloride supplier, Potent, AMPA, agonists, agonism, ketamine, metabolites, antidepressants, enantiomer, APJ, 2R,6R-HNK, depression, Receptors, Ketamine, and, Metabolites, 6094, Tocris Bioscience

10 Citations for 2R,6R-Hydroxynorketamine hydrochloride

Citations are publications that use Tocris products. Selected citations for 2R,6R-Hydroxynorketamine hydrochloride include:

Jian-Hua et al (2020) The Ventrolateral Periaqueductal Gray Contributes to Depressive-Like Behaviors in Recovery of Inflammatory Bowel Disease Rat Model. Front Neurosci 14 254 PMID: 32265648

Xiangmin et al (2020) Subanesthetic Ketamine Reactivates Adult Cortical Plasticity to Restore Vision from Amblyopia. Curr Biol 30 3591-3603.e8 PMID: 32822611

Eero et al (2019) Pharmacologically diverse antidepressants facilitate TRKB receptor activation by disrupting its interaction with the endocytic adaptor complex AP-2. J Biol Chem 294 18150-18161 PMID: 31631060

Ago et al (2019) (R)-Ketamine induces a greater increase in prefrontal 5-HT release than (S)-Ketamine and Ketamine Metabolites via an AMPA receptor-independent mechanism. Int J Neuropsychopharmacol 22 665 PMID: 31325908

Do you know of a great paper that uses 2R,6R-Hydroxynorketamine hydrochloride from Tocris? Please let us know.

Reviews for 2R,6R-Hydroxynorketamine hydrochloride

There are currently no reviews for this product. Be the first to review 2R,6R-Hydroxynorketamine hydrochloride and earn rewards!

Have you used 2R,6R-Hydroxynorketamine hydrochloride?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Addiction Poster

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.